Effepharm's UTHEVER® NMN: 66 people Human Clinical Trial Data Published, NAD+/NADH Level increased 38% in 2 months
7.6.2022 12:13:00 EEST | Business Wire | Press release
Effepharm Ltd creatively launched a branded NMN ingredient to bring the purest and safest NMN ingredient around the world. UTHEVER® NMN has been clinically proven to be safe and to improve the NAD+/NADH level in the human body, thus realizing the anti-aging function.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220607005649/en/
Figure 1 https://www.frontiersin.org/articles/10.3389/fragi.2922.851698/full (Graphic: Business Wire)
On 5th May 2022, Frontiers in Aging, an authoritative international journal on aging mechanisms, published one NMN clinical trial report with new insights and more experience being brought into the field of longevity.
Frontiers in Aging, one of the largest and highest-cited publishers in the world, led and peer-reviewed by editorial boards of over 100,000 top researchers, agreed to publish UTHEVER® NMN’s human clinical trial report, which was reviewed by scientists, including professors at Harvard Medical School. This is the first time that Effepharm released detailed trial data to the public.
Compared with previous NMN clinical trials involving dozens of people, the number of Effepharm’s UTHEVER® clinical trial was up to 66 people which is more conspicuous. At the end of the study (day 60), the level of NAD+/NADH increased further by 38% from baseline in the UTHEVER® group, compared to a mere 14.3% rise in the placebo group which might be attributed to the placebo effect. HOMA (homeostatic model assessment), 6 minute walking endurance test and SF-36 questionnaire were assessed to show that UTHEVER® has the potential to improve the quality of life and boost the happiness of the subjects under the test conditions.
Moreover, Effepharm as one of the leading manufacturer of NMN, has finished the toxicology tests of Uthever, which proved that Uthever is non-mutagenic and has no acute and sub-chronic toxicity. Although the test results are not publicly available now, they have laid a solid foundation for the evaluation of the safety of UTHEVER® NMN.
Effepharm’s R&D Director Jianjun Yu said: “ The clinical trials of UTHEVER® NMN is to establish a more professional and scientific image, helping the downstream supplement brand side get more power to do product endorsement and give more confidence to end consumers. Up to now, more and more well-known supplement brands such as Prohealth Longevity® in the USA, Do Not Age in UK, Kenay® Agescience, AFEGE Anti-aging Shop, MoleQlar in EU., VitaNAD+ in Japan etc. are using UTHEVER® trademark and realized the co-branding effects.”
Dr. Yu also revealed that the first period of NMN clinical trials mainly aimed to verify the safety of UTHEVER® NMN, so we designed a lower dosage to some extent. In the next few years, we will consider to conduct more NMN function researches to explore the safety of larger doses of NMN and the effectiveness of related indications on which this trial data are based. Effepharm Ltd will also apply for FDA Affirmed GRAS on NMN, which means that NMN raw material through the food regulations of various countries has taken a milestone step.
Reference:
https://www.frontiersin.org/articles/10.3389/fragi.2022.851698/full
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220607005649/en/
Contact information
Effepharm Ltd
marketing@effepharm.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Canada to Join the NATO Innovation Fund to Advance the Local Defence, Security and Resilience Ecosystem21.11.2026 18:00:00 EET | Press release
Canada announced today it is joining the NATO Innovation Fund, becoming the 25th Allied nation to commit to backing deep tech innovation to address the needs of NATO nations. The Government of Canada is committing EUR 64,590,000 (approximately CAD $100 million) to the firm, with the Business Development Bank of Canada (BDC) holding and managing Canada’s investment in the Fund. This brings total commitments to the NATO Innovation Fund to more than EUR 1.1 billion. Canadian membership will give domestic innovators access to patient capital, opportunities to accelerate the adoption of their technology by governments and businesses across the Alliance, a large network of co-investors, and lessons learned from the NIF’s work to date across 24 participating nations. “Canada has the talent, the innovation, and the ambition to be a global leader in defence and security. The NATO Innovation Fund is helping turn that potential into real capabilities by connecting Canadian innovators with the inv
Persona Earns CEN/TS 18099 High Certification for Injection Attack Detection21.11.2026 16:30:00 EET | Press release
Persona, the leading global identity platform, today announced that its Android SDK has earned CEN/TS 18099 High certification for injection attack detection (IAD). High certification is the top level of the European standard. The evaluation was run by CLR CERT, the certification body of Cabinet Louis Reynaud (CLR) Labs. CLR Labs is accredited under ISO/IEC 17025, the international standard for testing laboratories, and it edits CEN/TS 18099. This certificated injection attack detection is available to all Persona customers and can be activated by working with Persona's team. Injection attacks skip the camera entirely. Instead of holding a photo or mask up to a lens, fraudsters use virtual cameras, emulators and tampered devices to feed stolen, manipulated, or AI-generated media straight into the verification flow. To the system, the result looks like a real live capture, and traditional liveness checks aren't built to catch it. "Our customers are facing more sophisticated deepfakes, f
Verlinvest to Facilitate China Resources’ Full Exit From Oatly20.11.2026 23:30:00 EET | Press release
Verlinvest, the global, family-backed consumer-focused evergreen investment company, today announced it has entered into an agreement to acquire China Resources Enterprise, Limited’s (“China Resources”) indirect interests in Oatly Group AB (publ) (Nasdaq: OTLY) (“Oatly”), the world’s original and largest oat drink company. The transaction builds on Verlinvest’s investment in Oatly since 2016 and reinforces its conviction in the company’s long-term potential. A change in strategic direction of state-owned enterprise China Resources informed its decision to fully exit its investment in Oatly. China Resources worked constructively with Verlinvest to identify the best path for it to do so in recognition of the complexity of their joint holding structure. Under the agreement, Verlinvest will acquire China Resources’ indirect interests in Oatly’s equity and convertible instruments that are currently held through Verlinvest and China Resources’ joint venture vehicle, Nativus Company Limited.
Picsart Opens the AI Behind Its Platform to Developers & Businesses20.11.2026 21:54:00 EET | Press release
Picsart, the AI media production and distribution platform backed by Sequoia Capital and SoftBank Vision Fund 2, today launched Picsart Platform - a multimodal creative AI hub that gives developers the technology behind the platform used by more than 100 million people each month. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261120520968/en/ Picsart Opens the AI Behind Its Platform to Developers & Businesses. They can now build their own video, audio, image features using 250+ models from 30+ providers, alongside Picsart's own editing models, through one API, CLI or MCP server. As new video and image models launch every few weeks, managing separate APIs, API keys, and billing systems creates a fragmented ecosystem. By offering unified access to creative tools, Picsart Platform eliminates fragmentation for all creators, spanning independent developers and corporate marketing teams and studios, by providing access to over 25
NetJets Becomes Official Private Aviation Provider of the Hahnenkamm Races in Kitzbühel20.11.2026 19:45:00 EET | Press release
NetJets, the global leader in private aviation, is delighted to announce its newest partnership with the Hahnenkamm Races in Kitzbühel, Austria, becoming the event's Official Private Aviation Provider. The Hahnenkamm Races are among the most prestigious and celebrated events in world alpine skiing. They attract athletes, business leaders, international guests and winter sports enthusiasts from around the world. Through this partnership, NetJets and the Hahnenkamm Races are aligning two brands renowned for excellence, precision and world-class experiences. The partnership is an exciting addition to NetJets' growing portfolio of premium lifestyle and sporting partnerships, offering Owners unique opportunities to access one of Europe's most iconic winter sporting events. Alongside premium hospitality and unforgettable behind-the-scenes experiences, the collaboration will help create extraordinary moments for Owners, both in the air and on the ground in Kitzbühel. “Kitzbühel is synonymous
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
